According to current understanding, caspase-6 is an effector caspase that is activated downstream of caspase 3 during apoptosis 1, 2 and is essential only for the apoptotic cleavage of lamin A in nuclei that express this polypeptide. 3 On the other hand, several recent observations have raised the possibility that caspase 6 might also play an important upstream role during anticancer drug-induced apoptosis. First, based on the ability of IETD-fmk but not crmA or caspase 8 deficiency to inhibit resveratrol-induced apoptosis in human T-cell leukemia cell lines, it has been suggested that caspase 6 is the initiator caspase after treatment with this experimental anticancer agent. 4 Second, DU145 human prostate cancer cells selected for camptothecin resistance were observed to have diminished expression of procaspase-6. 5 More recently, experiments designed to measure procaspase polypeptide levels 6 in the 60 human tumor cell lines utilized by the National Cancer Institute to screen potential anticancer drugs 7, 8 demonstrated a striking correlation between procaspase 6 polypeptide levels and ability of certain agents to induce cell death (LC 50 ) across the cell lines ( Figure 1a and molecular target MT1646 at http://www.dtp.nci.nih.gov/webdata.html). Collectively, these observations raised the possibility that caspase 6 might play a previously unsuspected critical role in the induction of apoptosis after treatment with selected anticancer drugs.
To test this hypothesis, we examined the ability of a number of agents to induce apoptosis in parental and caspase-6 À/À DT40 chicken lymphoma cells. 3 Our data revealed that the ability of the topoisomerase II poison etoposide to induce apoptosis in the caspase-6 À/À cell line was intact (Figure 1b ) despite the absence of detectable procaspase-6 protein (Figure 1c) , ruling out the possibility that the gene targeting and selection process had raised the apoptotic threshold in this cell line. When treated with camptothecin, the parental and caspase-6 À/À cells displayed roughly equal sensitivity to the induction of apoptosis as assessed by the appearance of cells with subdiploid DNA content after propidium iodide staining (Figure 1d ) or the activation of caspase 3-like activity (Figure 1e ).
Among the compounds that showed a high correlation between procaspase-6 expression and LC 50 , several were not available for testing (not shown) or failed to induce apoptosis in DT40 cells after 48 h of continuous exposure to the highest tested concentration (Figure 1a) . Three of the agents, however, readily induced apoptosis in DT40 cells (Figure 1a and f). Of these three, two (NSC 349856 and NSC 682298) induced slightly more apoptosis in caspase-6 À/À DT40 cells than parental cells (Figure 1f ). In short, the loss of caspase-6 does not appear to impair the ability of any of these agents to induce apoptosis. Even though the correlations between caspase-6 content and drug sensitivity across 60 cell lines were striking and highly statistically significant for several compounds (Figure 1a) , we found no mechanistic basis for these correlations and no evidence that caspase 6 plays an essential role in the cytotoxic response to these agents. Figure 1 Relationship between procaspase-6 expression and drug sensitivity. (a) Correlation between procaspase 6 content and sensitivity to certain drugs. For each compound, R represents the Pearson correlation coefficient for results of assays that independently determined the relative procaspase-6 polypeptide levels in 60 human cancer cell lines by immunoblotting as recently described 6 and the drug concentration that decreased cell mass (determined by sulforhodamine blue binding after a 48 h exposure) 7, 8 to 50% of pretreatment levels (LD 50 ) in the same cell lines. A positive R value indicates that cells with high procaspase 6 levels are more sensitive. p represents the probability that this correlation would arise by chance alone. Structures of the compounds can be found at http://www.dtp.nci.nih.gov/webdata.html. The ability of these agents to induce apoptosis in DT40 cells as assessed by flow cytometry after treatment at 5 mg/ml for 48 h followed by propidium iodide staining and flow cytometry (see below) is also indicated. þ indicates apoptosis, Àindicates no apoptosis. (b) Comparison of etoposide sensitivity of parental and procaspase-6 À/À DT40 cells. After a 24 h exposure to 1 mM etoposide, cells were stained with 50 mg/ml propidium iodide in 0.1% (w/v) sodium citrate containing 0.1% (w/v) Triton X-100 at 41C overnight and then subjected to flow microfluorimetry as previously described. 9, 10 In this panel and subsequent panels, parental cells and caspase-6 À/À cells are represented by open and closed symbols, respectively. Bars, mean7S.E.M. of six independent experiments. *, P ¼ 0.013 by paired t-test. (c) Aliquots containing 50 mg (lanes 1, 4), 25 mg (lanes 2, 5), or 12.5 mg (lanes 3, 6) of total cellular protein from untreated cells were separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose, and sequentially probed with rabbit anti-chicken procaspase-6 3 (upper panel) and mouse anti-heat shock protein 90 (a kind gift from David Toft, Mayo Clinic, Rochester, MN) using previously described techniques.
11 (d) Cells were treated for 24 h with the indicated concentration of camptothecin or diluent (0.1% DMSO) and examined for the presence of subdiploid cells as described in panel b. Bars, mean7S.E.M. of three independent experiments. (e) After cells were treated for 24 h with 50 nM camptothecin (CPT) or diluent (0.1% dimethyl sulfoxide), cytosol was prepared and assayed for activity capable of cleaving the caspase 3/7-preferred substrate DEVD-AFC and the caspase 6-preferred substrate VEID-AFC as previously described. 12 Bars, mean7S.E.M. of four independent experiments. (f) Cells were treated for 24 h with the indicated investigational anticancer agent at 5 mg/ml (added from a 1000-fold concentrated stock in dimethyl sulfoxide), stained, and examined for subdiploid cells as described for panel b. Flavopiridol (1 mM), a PTEF-b inhibitor 13 that triggers apoptosis by inducing cytochrome c release from mitochondria, 14 was included as an agent that should not be affected by procaspase 6 expression in these assays. Bars, mean7S.E.M. of four to six independent experiments for various drugs. *, **P ¼ 0.05 and P ¼ 0.03, respectively, by paired t-test. P-values in these panels have not been corrected for any effect of multiple comparisons
